Generated by AI
Senti Biosciences Holdings, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies built with its proprietary Gene Circuit platform. The company designs engineered medicines that can sense biological signals, make programmed decisions, and respond with greater precision in complex disease environments. Its current work centers on advanced cell therapies for difficult-to-treat cancers and other incurable diseases, with applications across both liquid and solid tumors. Senti Biosciences Holdings, Inc. develops these programs using synthetic biology tools intended to improve targeting, control, and selectivity in therapeutic cells. Headquartered in South San Francisco, California, the company operates in the biotechnology and cell therapy markets, where it contributes to the broader effort to create more precise and controllable genetic medicines.
Website2 Corporate Drive
South San Francisco, CA, 94080
United States
The latest articles about SNTI.
Tipranks Press Release.
Summary of Oct 27's posts. Generated by AI.
Summary of Oct 27's posts. Generated by AI.
Summary of Oct 27's posts. Generated by AI.
Investors talking about SNTI also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.